Since the firm's founding in 2007, Adynxx Inc. (since May 2019 now NASDAQ: ADYX) - a clinical-stage biopharmaceutical company - had been structured around development of transcription factor decoy technology and first-in-class therapeutics for the treatment of pain and inflammatory diseases. In May 2019, Adynxx, Inc. merged with the publicly traded firm Alliqua Biomedical, In connection with the merger, Alliqua changed its name to Adynxx, Inc. with the combined organization structured to operate under the leadership of the original Adynxx management team in place prior to the merger, The new entiity commenced trading on the Nasdaq Capital Market uat that time under the symbol âADYX.â Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. The firm is involved in development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pa
